Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: A retrospective analysis

Chemotherapy

Volumn 59, Issue 4, 2014, Pages 280-289

  Hus, Iwona ^a   Jawniak, Dariusz ^a   Gorska Kosicka, Magdalena ^a   Butrym, Aleksandra ^b   Dzietczenia, Justyna ^b   Wrobel, Tomasz ^b   Grzegorz, Mazur ^b   Lech Maranda, Ewa ^c   Warzocha, Krzysztof ^c   Waszczuk Gajda, Anna ^c   Jedrzejczak, W Wiktor ^c   Krawczyk Kulis, Małgorzata ^e   Kyrcz Krzemien, Sławomira ^e   Poplawska, Lidia ^d   Walewski, Jan ^d   Dmoszynska, Anna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

B cell malignancies; Bendamustine; Chronic lymphocytic leukemia; Non Hodgkin lymphoma

Indexed keywords

BENDAMUSTINE; BETA 2 MICROGLOBULIN; RITUXIMAB; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERY ELDERLY; CONTROLLED STUDY; DRUG DOSE REGIMEN; GLOBULIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; PROGRESSION FREE SURVIVAL;

AGED; AGED, 80 AND OVER; ANEMIA; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; NITROGEN MUSTARD COMPOUNDS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 84892722819     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000357468     Document Type: Article

References (36)

1. Rodriguez-Abreu D, Bordoni A, Zucca E: Epidemiology of hematological malignancies. Ann Oncol 2007; 18(suppl 1):i3-i8
2. Motta G, Cea M, Moran E, et al: Monoclonal antibodies for non-Hodgkin's lymphoma: State of the art and perspectives. Clin Dev Immunol 2010; 2010: 428253
3. Winter MC, Hancock BW: Ten years of rituximab in NHL. Expert Opin Drug Saf 2009; 8: 223-235
4. Pettengell R, Aapro M, Brusamolino E, et al: Implications of the European Organisation for Research and Treatment of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care. Clin Drug Investig 2009; 29: 491-513
5. Yang BB, Savin MA, Green M: Prevention of chemotherapy-induced neutropenia with pegfilgrastim: Pharmacokinetics and patient outcomes. Chemotherapy 2012; 58: 387-398
6. Hallek M, Fischer K, Fingerle-Rowson G, et al, International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174
7. Robak T, Dmoszynska A, Solal-Celigny P, et al: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukaemia. J Clin Oncol 2010; 28: 1756-1765
8. Hallek M: Therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010; 23: 85-96
9. Kath R, Blumenstengel K, Fricke HJ, Hoffken K: Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukaemia. J Cancer Res Clin Oncol 2001; 127: 48-54
10. Herold M, Anger G, Hoche D, Kastner R: Preliminary results of cyclically alternating chemotherapy (CVPP/DBVCy) in advanced Hodgkin's disease (in German). Med Klin (Munich) 1987; 82: 345-349
11. Hoffken K, Merkle K, Schonfelder M, et al: Bendamustine as salvage treatment in patients with advanced progressive breast cancer: A phase II study. J Cancer Res Clin Oncol 1998; 124: 627-632
12. Gandhi V: Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies. Semin Oncol 2002; 29(suppl 13): 4-11
13. Roue G, Lopez-Guerra M, Milpied P, et al: Bendamustine is effective in p53-deficient Bcell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008; 14: 6907-6915
14. Leoni LM, Bailey B, Reifert J, et al: Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309-317
15. Kanekal S, Crain B, Elliot TG: SDX105 (Treanda) enhances the tumor growth inhibitory effect of rituximab in Daudi lymphoma xenografts (abstract 4580). Blood 2004; 104: 229b.
16. Chow KU, Sommerlad WD, Boehrer S, et al: Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 2002; 87: 33-43
17. Hallek M, Cheson BD, Catovsky D, et al, International Workshop on Chronic Lymphocytic Leukemia: Guidelines for the diagnosis and treatment of chronic lymphocytic leukaemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 1119: 5446-5456
18. Cheson BD, Pfistner B, Juweid ME, et al: International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586
19. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) v3.0. http:ctep.info.nih.gov/protocol Development/electronic-applications/ctc. htm#ctc.-30
20. Fischer K, Cramer P, Busch R, et al: Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukaemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29: 3559-3566
21. Iannitto E, Morabito F, Mancuso S, et al: Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: An Italian retrospective study. Br J Haematol 2011; 153: 351-357
22. Sanchez-Gonzalez B, Penalver FJ, Medina A, et al: Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukaemia in Spain. Leuk Res 2012; 36: 709-714
23. Hus I, Podhorecka M, Bojarska-Junak A, et al: The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006; 17: 683-690
24. Del Principe MI, Del Poeta G, Buccisano F, et al: Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukaemia. Blood 2006; 108: 853-861
25. Tam CS, O'Brien S, Wierda W, et al: Longterm results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukaemia. Blood 2008; 112: 975-980
26. Wierda WG, Kipps TJ, Durig J, et al, 407 Study Investigators: Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukaemia. Blood 2011; 117: 6450-6458
27. Cheson BD, Wendtner CM, Pieper A, et al: Optimal use of bendamustine in chronic lymphocytic leukaemia, non-Hodgkin lymphomas, and multiple myeloma: Treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010; 10: 21-27
28. Friedberg JW, Cohen P, Chen L, et al: Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single- agent study. J Clin Oncol 2008; 26: 204-210
29. Kahl BS, Bartlett NL, Leonard JP, et al: Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non- Hodgkin lymphoma: Results from a multicenter study. Cancer 2010; 116: 106-114
30. Rummel MJ, Al-Batran SE, Kim SZ, et al: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non- Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383-3389
31. Robinson KS, Williams ME, van Der Jagt RH, et al: Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473-4479
32. Fowler N, Kahl BS, Lee P, et al: Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study. J Clin Oncol 2011; 29: 3389-3395
33. Friedberg JW, Vose JM, Kelly JL, et al: The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/ refractory indolent and mantle cell non- Hodgkin lymphoma. Blood 2011; 117: 2807-2812
34. Visani G, Malerba L, Stefani PM, et al: BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/ relapsed lymphoma patients. Blood 2011; 118: 3419-3425
35. Rummel MJ, Niederle N, Maschmeyer G, et al, Study group indolent Lymphomas (StiL): Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210
36. Rigacci L, Puccini B, Cortelazzo S, et al: Bendamustine with or without rituximab for the treatment of heavily pretreated non- Hodgkin's lymphoma patients: A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol 2012; 91: 1013-1022